.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Colorcon
Daiichi Sankyo
Boehringer Ingelheim
Citi
Johnson and Johnson
Fish and Richardson
UBS
Argus Health
QuintilesIMS

Generated: December 16, 2017

DrugPatentWatch Database Preview

Claims for Patent: 8,546,437

« Back to Dashboard

Claims for Patent: 8,546,437

Title:Compounds and compositions and methods of use
Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
Inventor(s): Quart; Barry D. (Encinitas, CA), Girardet; Jean-Luc (San Diego, CA), Gunic; Esmir (San Diego, CA), Yeh; Li-Tain (Irvine, CA)
Assignee: Ardea Biosciences, Inc. (San Diego, CA)
Application Number:13/174,594
Patent Claims: 1. A method of treating hyperuricemia in a human, the method comprising administering to the human a compound of formula (III): ##STR00178## wherein X is N; W is S or O; R.sup.1 is Cl, Br, I, optionally substituted methyl, CF.sub.3, CHF.sub.2 or CH.sub.2F; R.sup.3 and R.sup.3' are independently selected from H and lower alkyl; R.sup.2 is: ##STR00179## wherein represents a carbon-carbon double bond; R.sup.P is cyclopropyl; R.sup.8, R.sup.9 and R.sup.10 are H or a pharmaceutically acceptable salt, ester, or tautomer thereof.

2. The method of claim 1, wherein W is S.

3. The method of claim 1, wherein R.sup.3 and R.sup.3' are H.

4. The method of claim 2, wherein R.sup.3 and R.sup.3' are H.

5. The method of claim 1, wherein R.sup.1 is Br.

6. The method of claim 4, wherein R.sup.1 is Br.

7. The method of claim 1, wherein a compound of formula (IV): ##STR00180## or a pharmaceutically acceptable salt, ester, or tautomer thereof, is administered to the human.

8. The method of claim 1, wherein the pharmaceutically acceptable salt is administered to the human, and wherein the pharmaceutically acceptable salt is an ammonium, a primary amine, a secondary amine, a tertiary amine, a lithium, a sodium, a potassium, a calcium, a magnesium, or an aluminum salt.

9. The method of claim 8, wherein the pharmaceutically acceptable salt is a sodium salt.

10. The method of claim 1, wherein said administering is orally.

11. The method of claim 1, wherein said compound is administered in combination with a pharmaceutically acceptable carrier, excipient, or diluent, in a pharmaceutical composition.

12. The method of claim 11, wherein the pharmaceutical composition is a tablet or capsule.

13. The method of claim 11, wherein the pharmaceutical composition is a tablet.

14. The method of claim 13, wherein the pharmaceutical composition is a coated tablet.

15. The method of claim 13, wherein the tablet comprises lactose.

16. The method of claim 13, wherein the tablet comprises microcrystalline cellulose.

17. The method of claim 13, wherein the tablet comprises sodium croscarmellose.

18. The method of claim 12, wherein the tablet or capsule comprises gelatin.

19. The method of claim 13, wherein the tablet comprises magnesium stearate.

20. The method of claim 13, wherein the tablet comprises hydroxypropylcellulose or hydroxypropylmethyl-cellulose.

21. The method of claim 1, further comprising administering to the human a second agent effective for treatment of gout.

22. The method of claim 21, wherein the second agent is a URAT 1 inhibitor, a xanthine oxidase inhibitor, a xanthine dehydrogenase, a xanthine oxidoreductase inhibitor, or a combination thereof.

23. The method of claim 21, wherein the second agent is allopurinol, febuxostat, FYX-051, or a combination thereof.

24. The method of claim 21, wherein the second agent is allopurinol.

25. A method of treating hyperuricemia in a human, the method comprising administering to the human a compound of formula (IV): ##STR00181##
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Federal Trade Commission
Covington
QuintilesIMS
Moodys
McKesson
US Army
US Department of Justice
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot